Trial Outcomes & Findings for A Study of Colesevelam in Fecal Incontinence (NCT NCT02628626)

NCT ID: NCT02628626

Last Updated: 2023-06-22

Results Overview

The number of participants that report a 50% or greater reduction in weekly incontinent episodes as measured by self-reported bowel diaries.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

88 participants

Primary outcome timeframe

4 weeks

Results posted on

2023-06-22

Participant Flow

Eighty-eight (88) participants were enrolled but thirty-two (32) withdrew from the study before beginning any study procedures.

Participant milestones

Participant milestones
Measure
Placebo
Participants in this arm will receive placebo for 4 weeks. Placebo: Placebo will be identical in appearance to the active drug.
Colesevelam and Clonidine
Participants in this arm will receive a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) for 4 weeks. Colesevelam: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks. Clonidine: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
Overall Study
STARTED
32
24
Overall Study
COMPLETED
30
22
Overall Study
NOT COMPLETED
2
2

Reasons for withdrawal

Reasons for withdrawal
Measure
Placebo
Participants in this arm will receive placebo for 4 weeks. Placebo: Placebo will be identical in appearance to the active drug.
Colesevelam and Clonidine
Participants in this arm will receive a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) for 4 weeks. Colesevelam: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks. Clonidine: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
Overall Study
Withdrawal by Subject
2
2

Baseline Characteristics

A Study of Colesevelam in Fecal Incontinence

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Placebo
n=32 Participants
Participants in this arm will receive placebo for 4 weeks. Placebo: Placebo will be identical in appearance to the active drug.
Colesevelam and Clonidine
n=24 Participants
Participants in this arm will receive a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) for 4 weeks. Colesevelam: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks. Clonidine: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
Total
n=56 Participants
Total of all reporting groups
Age, Continuous
47 years
STANDARD_DEVIATION 26 • n=99 Participants
53 years
STANDARD_DEVIATION 29 • n=107 Participants
50 years
STANDARD_DEVIATION 27 • n=206 Participants
Sex: Female, Male
Female
32 Participants
n=99 Participants
24 Participants
n=107 Participants
56 Participants
n=206 Participants
Sex: Female, Male
Male
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Asian
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
White
32 Participants
n=99 Participants
24 Participants
n=107 Participants
56 Participants
n=206 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Region of Enrollment
United States
32 participants
n=99 Participants
24 participants
n=107 Participants
56 participants
n=206 Participants

PRIMARY outcome

Timeframe: 4 weeks

The number of participants that report a 50% or greater reduction in weekly incontinent episodes as measured by self-reported bowel diaries.

Outcome measures

Outcome measures
Measure
Placebo
n=30 Participants
Participants in this arm will receive placebo for 4 weeks. Placebo: Placebo will be identical in appearance to the active drug.
Colesevelam and Clonidine
n=22 Participants
Participants in this arm will receive a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) for 4 weeks. Colesevelam: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks. Clonidine: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
Number of Participants to Report a 50% or Greater Reduction in Weekly Fecal Incontinence (FI) Episodes
17 Participants
13 Participants

SECONDARY outcome

Timeframe: 4 weeks

The number of bowel movements daily measured by self-reported bowel diaries.

Outcome measures

Outcome measures
Measure
Placebo
n=30 Participants
Participants in this arm will receive placebo for 4 weeks. Placebo: Placebo will be identical in appearance to the active drug.
Colesevelam and Clonidine
n=22 Participants
Participants in this arm will receive a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) for 4 weeks. Colesevelam: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks. Clonidine: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
Daily Stool Frequency
2.4 bowel movements per day
Standard Deviation 2.3
2.1 bowel movements per day
Standard Deviation 2.0

SECONDARY outcome

Timeframe: 4 weeks

Stool consistency as measured by self-reported bowel diaries. Expressed in terms of the Bristol Stool Form Scale, where: 1= separate hard lumps; 2= lumpy sausage-shape; 3= cracked sausage; 4= smooth and soft sausage; 5=soft blobs; 6=mushy, fluffy pieces; 7= watery, no solid pieces.

Outcome measures

Outcome measures
Measure
Placebo
n=30 Participants
Participants in this arm will receive placebo for 4 weeks. Placebo: Placebo will be identical in appearance to the active drug.
Colesevelam and Clonidine
n=22 Participants
Participants in this arm will receive a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) for 4 weeks. Colesevelam: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks. Clonidine: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
Stool Consistency
4.1 score on a scale
Standard Deviation 1.9
3.2 score on a scale
Standard Deviation 1.5

SECONDARY outcome

Timeframe: 4 weeks

The number of stools per week measured by self-reported bowel diaries where the Bristol stool score was 5, 6, or 7. (5=soft blobs; 6=mushy, fluffy pieces; 7= watery, no solid pieces)

Outcome measures

Outcome measures
Measure
Placebo
n=30 Participants
Participants in this arm will receive placebo for 4 weeks. Placebo: Placebo will be identical in appearance to the active drug.
Colesevelam and Clonidine
n=22 Participants
Participants in this arm will receive a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) for 4 weeks. Colesevelam: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks. Clonidine: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
Number of Semi-Formed Stools Per Week
1.0 number of stools per week
Standard Deviation 0.7
1.2 number of stools per week
Standard Deviation 1.1

SECONDARY outcome

Timeframe: 4 weeks

The time in minutes a bowel movement can be delayed after sense of urgency to defecate as measured by self-reported bowel diaries.

Outcome measures

Outcome measures
Measure
Placebo
n=30 Participants
Participants in this arm will receive placebo for 4 weeks. Placebo: Placebo will be identical in appearance to the active drug.
Colesevelam and Clonidine
n=22 Participants
Participants in this arm will receive a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) for 4 weeks. Colesevelam: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks. Clonidine: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
Delay of Bowel Movement
2.8 minutes
Standard Deviation 7.8
3.6 minutes
Standard Deviation 8.4

SECONDARY outcome

Timeframe: 4 weeks

The total number of fecal incontinence episodes per week as measured by self-reported bowel diaries.

Outcome measures

Outcome measures
Measure
Placebo
n=30 Participants
Participants in this arm will receive placebo for 4 weeks. Placebo: Placebo will be identical in appearance to the active drug.
Colesevelam and Clonidine
n=22 Participants
Participants in this arm will receive a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) for 4 weeks. Colesevelam: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks. Clonidine: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
Total Fecal Incontinence Episodes
4.2 incontinence episodes per week
Standard Deviation 4.4
4.8 incontinence episodes per week
Standard Deviation 3.7

SECONDARY outcome

Timeframe: 4 weeks

The volume of fecal incontinence measured as the number of incontinent episodes per week as categorized by small (staining only), moderate (requiring change of underwear) or large (requiring change of all clothes) in self-reported bowel diaries.

Outcome measures

Outcome measures
Measure
Placebo
n=30 Participants
Participants in this arm will receive placebo for 4 weeks. Placebo: Placebo will be identical in appearance to the active drug.
Colesevelam and Clonidine
n=22 Participants
Participants in this arm will receive a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) for 4 weeks. Colesevelam: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks. Clonidine: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
Volume of Fecal Incontinence
Small (staining only)
2.4 incontinent episodes per week
Standard Deviation 1.8
3.3 incontinent episodes per week
Standard Deviation 3.0
Volume of Fecal Incontinence
Moderate (requires change of underwear)
0.9 incontinent episodes per week
Standard Deviation 1.7
2.0 incontinent episodes per week
Standard Deviation 2.6
Volume of Fecal Incontinence
Large (requires complete change of clothes
1.3 incontinent episodes per week
Standard Deviation 2.2
2.4 incontinent episodes per week
Standard Deviation 6.2

SECONDARY outcome

Timeframe: baseline

The percentage of bowel movements that were incontinent prior to treatment initiation, per self-reported bowel diaries.

Outcome measures

Outcome measures
Measure
Placebo
n=1362 Bowel Movements
Participants in this arm will receive placebo for 4 weeks. Placebo: Placebo will be identical in appearance to the active drug.
Colesevelam and Clonidine
n=1013 Bowel Movements
Participants in this arm will receive a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) for 4 weeks. Colesevelam: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks. Clonidine: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
Percent of Incontinent Bowel Movements Pre-treatment
45 percent of incontinent bowel movements
Standard Deviation 9
40 percent of incontinent bowel movements
Standard Deviation 10

SECONDARY outcome

Timeframe: 4 weeks

The percentage of bowel movements that were incontinent during treatment, per self-reported bowel diaries.

Outcome measures

Outcome measures
Measure
Placebo
n=1419 Bowel Movements
Participants in this arm will receive placebo for 4 weeks. Placebo: Placebo will be identical in appearance to the active drug.
Colesevelam and Clonidine
n=1086 Bowel Movements
Participants in this arm will receive a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) for 4 weeks. Colesevelam: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks. Clonidine: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
Percent of Incontinent Bowel Movements During Treatment
27 percent of incontinent bowel movements
Standard Deviation 8
28 percent of incontinent bowel movements
Standard Deviation 9

SECONDARY outcome

Timeframe: baseline

The percentage of incontinent bowel movements where the Bristol stool score was 5, 6 or 7. (5=soft blobs; 6=mushy, fluffy pieces; 7= watery, no solid pieces), pre-treatment, per self-reported bowel diaries.

Outcome measures

Outcome measures
Measure
Placebo
n=613 Incontinent Bowel Movements
Participants in this arm will receive placebo for 4 weeks. Placebo: Placebo will be identical in appearance to the active drug.
Colesevelam and Clonidine
n=405 Incontinent Bowel Movements
Participants in this arm will receive a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) for 4 weeks. Colesevelam: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks. Clonidine: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
Percent of Incontinent Bowel Movements to be Semi-Formed Stools Pre-Treatment
61 percent of semi-formed stools
Standard Deviation 8
76 percent of semi-formed stools
Standard Deviation 8

SECONDARY outcome

Timeframe: 4 weeks

The percentage of incontinent bowel movements where the Bristol stool score was 5, 6 or 7. (5=soft blobs; 6=mushy, fluffy pieces; 7= watery, no solid pieces) during treatment, per self-reported bowel diaries.

Outcome measures

Outcome measures
Measure
Placebo
n=383 Incontinent Bowel Movements
Participants in this arm will receive placebo for 4 weeks. Placebo: Placebo will be identical in appearance to the active drug.
Colesevelam and Clonidine
n=304 Incontinent Bowel Movements
Participants in this arm will receive a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) for 4 weeks. Colesevelam: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks. Clonidine: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
Percent of Incontinent Bowel Movements to be Semi-Formed Stools During Treatment
67 percent of semi-formed stools
Standard Deviation 8
61 percent of semi-formed stools
Standard Deviation 10

SECONDARY outcome

Timeframe: 4 weeks

The Fecal Incontinence Symptom Severity (FISS) score is based on five questions; (1) the frequency of FI; (2) the type of FI (stool only, liquid or mucus only, both liquid/mucus and stool, or gas only); (3) the amount of stool leaked (small, moderate, or large); (4) the frequency of having to rush to the toilet; and (5) the frequency of having stool leak without warning. Questions 4 \& 5 are merged to determine if the participant has passive FI (FI without warning), urge FI, both, or neither. The responses to the questions are assigned physician-derived weights and added together for a total score of 4 to 13. The higher the score the more severe the FI symptoms.

Outcome measures

Outcome measures
Measure
Placebo
n=30 Participants
Participants in this arm will receive placebo for 4 weeks. Placebo: Placebo will be identical in appearance to the active drug.
Colesevelam and Clonidine
n=22 Participants
Participants in this arm will receive a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) for 4 weeks. Colesevelam: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks. Clonidine: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
Severity of Bowel Symptoms
6 score on a scale
Standard Deviation 3.2
4.6 score on a scale
Standard Deviation 3.6

SECONDARY outcome

Timeframe: 4 weeks

Measured by the Fecal Incontinence Severity Index (FISI). It is a validated 4-item scale used to assess the frequency (never, 1-3 times a month, once a week, 2 or more times per week but not daily, once a day, 2 or more times per day) of 4 different types of FI (gas, mucus, liquid stool, solid stool). Each of the four types of FI is awarded a number of points, depending on the frequency at which that type of incontinence is experienced. The points are totaled and the scores can range from 0 to 61, where the higher the score, the higher the perceived severity of the fecal incontinence.

Outcome measures

Outcome measures
Measure
Placebo
n=30 Participants
Participants in this arm will receive placebo for 4 weeks. Placebo: Placebo will be identical in appearance to the active drug.
Colesevelam and Clonidine
n=22 Participants
Participants in this arm will receive a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) for 4 weeks. Colesevelam: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks. Clonidine: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
Severity of Fecal Incontinence
28 score on a scale
Standard Deviation 15
22 score on a scale
Standard Deviation 18

SECONDARY outcome

Timeframe: 4 weeks

The Fecal Incontinence Quality of Life questionnaire measures specific quality of life issues expected to affect patients with fecal incontinence. The questions are grouped into four categories: lifestyle (10 questions), coping (9 questions), depression (7 questions), and embarrassment (3 questions). Each category is scored from 1 to 4. The scale scores are calculated by adding the numerical values of all responses in that specific scale and then dividing by its number of items. Higher scores indicate a better quality of life.

Outcome measures

Outcome measures
Measure
Placebo
n=30 Participants
Participants in this arm will receive placebo for 4 weeks. Placebo: Placebo will be identical in appearance to the active drug.
Colesevelam and Clonidine
n=22 Participants
Participants in this arm will receive a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) for 4 weeks. Colesevelam: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks. Clonidine: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
Fecal Incontinence Quality of Life (FI-QoL)
Lifestyle score
2.7 score on a scale
Standard Deviation 0.9
2.7 score on a scale
Standard Deviation 0.9
Fecal Incontinence Quality of Life (FI-QoL)
Coping score
2.0 score on a scale
Standard Deviation 0.6
2.1 score on a scale
Standard Deviation 0.8
Fecal Incontinence Quality of Life (FI-QoL)
Depression Score
3.1 score on a scale
Standard Deviation 0.6
3.1 score on a scale
Standard Deviation 0.8
Fecal Incontinence Quality of Life (FI-QoL)
Embarrassment score
2.6 score on a scale
Standard Deviation 0.9
2.5 score on a scale
Standard Deviation 0.9

SECONDARY outcome

Timeframe: 4 weeks

The number of tablets of loperamide used, per self-reported bowel diaries.

Outcome measures

Outcome measures
Measure
Placebo
n=30 Participants
Participants in this arm will receive placebo for 4 weeks. Placebo: Placebo will be identical in appearance to the active drug.
Colesevelam and Clonidine
n=22 Participants
Participants in this arm will receive a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) for 4 weeks. Colesevelam: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks. Clonidine: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
Loperamide Tablets Per Week
1.9 tablets per week
Standard Deviation 2
6 tablets per week
Standard Deviation 5

Adverse Events

Placebo

Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths

Colesevelam and Clonidine

Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Placebo
n=32 participants at risk
Participants in this arm will receive placebo for 4 weeks. Placebo: Placebo will be identical in appearance to the active drug.
Colesevelam and Clonidine
n=24 participants at risk
Participants in this arm will receive a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) for 4 weeks. Colesevelam: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks. Clonidine: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
General disorders
Nausea and bloating
0.00%
0/32 • Adverse events were collected from baseline to the end of study participation, for a total of approximately 12 weeks on each participant.
8.3%
2/24 • Number of events 2 • Adverse events were collected from baseline to the end of study participation, for a total of approximately 12 weeks on each participant.
General disorders
Intercurrent Illness
3.1%
1/32 • Number of events 1 • Adverse events were collected from baseline to the end of study participation, for a total of approximately 12 weeks on each participant.
8.3%
2/24 • Number of events 2 • Adverse events were collected from baseline to the end of study participation, for a total of approximately 12 weeks on each participant.
General disorders
Difficulty swallowing pills
6.2%
2/32 • Number of events 2 • Adverse events were collected from baseline to the end of study participation, for a total of approximately 12 weeks on each participant.
8.3%
2/24 • Number of events 2 • Adverse events were collected from baseline to the end of study participation, for a total of approximately 12 weeks on each participant.
General disorders
Insomnia
3.1%
1/32 • Number of events 1 • Adverse events were collected from baseline to the end of study participation, for a total of approximately 12 weeks on each participant.
0.00%
0/24 • Adverse events were collected from baseline to the end of study participation, for a total of approximately 12 weeks on each participant.

Additional Information

Dr. Adil Bharucha

Mayo Clinic

Phone: 507-284-2687

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place